4-[(2,6-difluorophenyl)methyl]-6-[(6-ethylsulfonyl-3-pyridinyl)oxy]-2-pyrazin-2-yl-1H-benzimidazole
C25H19F2N5O3S — CID 11691936
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[(2,6-difluorophenyl)methyl]-6-[(6-ethylsulfonyl-3-pyridinyl)oxy]-2-pyrazin-2-yl-1H-benzimidazole
4-[(2,6-difluorophenyl)methyl]-6-[(6-ethylsulfonyl-3-pyridinyl)oxy]-2-pyrazin-2-yl-1H-benzimidazole (PubChem CID 11691936) has the molecular formula C25H19F2N5O3S and a molecular weight of 507.52 g/mol. Its IUPAC name is 4-[(2,6-difluorophenyl)methyl]-6-[(6-ethylsulfonyl-3-pyridinyl)oxy]-2-pyrazin-2-yl-1H-benzimidazole.
Molecular Properties
| Compound Name | 4-[(2,6-difluorophenyl)methyl]-6-[(6-ethylsulfonyl-3-pyridinyl)oxy]-2-pyrazin-2-yl-1H-benzimidazole |
|---|---|
| PubChem CID | 11691936 |
| Molecular Formula | C25H19F2N5O3S |
| Molecular Weight | 507.52 g/mol |
| Exact Mass | 507.12 |
| IUPAC Name | 4-[(2,6-difluorophenyl)methyl]-6-[(6-ethylsulfonyl-3-pyridinyl)oxy]-2-pyrazin-2-yl-1H-benzimidazole |
| SMILES | CCS(=O)(=O)c1ccc(Oc2cc(Cc3c(F)cccc3F)c3nc(-c4cnccn4)[nH]c3c2)cn1 |
| InChI | InChI=1S/C25H19F2N5O3S/c1-2-36(33,34)23-7-6-16(13-30-23)35-17-10-15(11-18-19(26)4-3-5-20(18)27)24-21(12-17)31-25(32-24)22-14-28-8-9-29-22/h3-10,12-14H,2,11H2,1H3,(H,31,32) |
| InChIKey | YZDLWRYYMGHQHB-UHFFFAOYSA-N |
| XLogP | 4.87 |
| TPSA | 110.72 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 36 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 507.52 |
| LogP ≤ 5 | 4.87 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 11691936 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.